QIAstat-Dx Respiratory SARS-CoV-2 Panel

Be the first to know about QIAstat-Dx updates

Clinicians want accurate and timely answers.
Patients want the right treatment.

Powered by proven QIAGEN sample and assay technologies, you can now confidently provide clinical insights to patients with the highest level of versatility and harness the full potential of multiplex syndromic testing.

Learn more about QIAstat-Dx

QIAstat-Dx Respiratory SARS-CoV-2 Panel
(Emergency Use Authorization)

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 21 respiratory targets, including SARS-CoV-2.

Learn more

*Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

QIAGEN is committed to supporting healthcare workers fight COVID-19

Visit www.qiagen.com/coronavirus to learn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.

QIAstat-Dx – changing the landscape of multiplex respiratory testing

Multiplex syndromic testing rapidly and simultaneously surveys a large number of pathogens, giving you the answers you need when you need them. Check out our infographic and learn more about syndromic testing for respiratory disease on the QIAstat-Dx!

Download Infographic

See QIAstat-Dx in action

How can we support your work?

Reach a specialist
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Social Sharing